Global Peptide Therapeutics Market

Peptide Therapeutics Market Size, Share, Growth Analysis, By Type (Generic and Innovative), By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain), By Type of Manufacturers, By Region -Industry Forecast 2026-2033

Report ID: SQMIG35I2435 | Region: Global | Published Date: August, 2025
Pages: 173 |Tables: 96 |Figures: 71

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Peptide Therapeutics Market size was valued at USD 45.67 Billion in 2024 poised to grow between USD 48.38 Billion in 2025 to USD 76.77 Billion by 2033, growing at a CAGR of 5.94% in the forecast period (2026–2033).

    The global peptide therapeutics market outlook is highly competitive, with key players including Eli Lilly, Novo Nordisk, Amgen, Takeda, and Ipsen. Companies focus on strategic collaborations, product innovation, and expanding peptide drug pipelines. For example, Novo Nordisk advances GLP-1 peptide drugs for diabetes and obesity, while Eli Lilly invests in AI-powered peptide discovery. Takeda emphasizes rare disease peptides, strengthening its position through acquisitions and global research partnerships. 'Amgen Inc. (USA)', 'Eli Lilly and Company (USA)', 'Pfizer Inc. (USA)', 'Novo Nordisk A/S (Denmark)', 'Sanofi S.A. (France)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Ipsen S.A. (France)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Bachem Holding AG (Switzerland)', 'AstraZeneca plc (United Kingdom)', 'F. Hoffmann-La Roche AG (Switzerland)', 'Cipla Limited (India)', 'Lonza Group AG (Switzerland)', 'CordenPharma International GmbH (Germany)', 'Sun Pharmaceutical Industries Ltd. (India)'

    The increasing global incidence of chronic conditions such as diabetes, cancer, and cardiovascular disorders is a major driver of peptide therapeutics. Peptides offer targeted, effective treatment with fewer side effects, making them ideal for managing long-term illnesses. This rising disease burden fuels demand for advanced, peptide-based pharmaceutical solutions.

    Rising Adoption of Peptide–Drug Conjugates: Peptide–drug conjugates are increasingly utilized for targeted therapies, especially in oncology. They combine the precision of peptides with potent cytotoxic agents, minimizing side effects. This innovation supports precision medicine and is attracting pharmaceutical investments, significantly enhancing the therapeutic efficacy of peptide-based treatments in the global peptide therapeutics market.

    What Role does R&D Investments Play in North America’s Peptide Therapeutics Sector?

    Related Reports

    Protein Therapeutics Market
    Buy Now GET FREE SAMPLE
    Collagen Peptides Market
    Buy Now GET FREE SAMPLE
    Targeted Therapeutics Market
    Buy Now GET FREE SAMPLE
    Cancer Therapeutics Market
    Buy Now GET FREE SAMPLE
    mRNA Therapeutics Market
    Buy Now GET FREE SAMPLE
    Infectious Disease Therapeutics Market
    Buy Now GET FREE SAMPLE
    Autism Spectrum Disorder Therapeutics Market
    Buy Now GET FREE SAMPLE
    Nucleic Acid Therapeutics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Peptide Therapeutics Market

    Report ID: SQMIG35I2435

    $5,300
    BUY NOW